Heavy spending worries in big tech have already erased over US$1t in market value, yet the same rush into artificial intelligence is reshaping Australian healthcare. That tension creates a window. Money is pouring into AI tools that could cut hospital costs, sharpen diagnoses, and speed drug research. This article walks through three AI driven healthcare stocks from our screener that aim to tap into that shift.
The three stocks below are a sample pulled from a wider screen, and that broader search surfaced 3 more AI driven healthcare companies with equally compelling narratives that are not covered in this article.
If you want to identify, compare, and analyze those extra opportunities alongside the ideas discussed here, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener .
ImExHS (ASX:IME)
ImExHS uses its AQUILA, ANTEROS and ALULA imaging platforms, together with teleradiology services, to turn real clinical images and radiologist reports into data fuel for AI driven diagnostics across hospitals and remote care settings.
ImExHS generates about A$10 million from software and A$21 million from radiology services, and has a market cap near A$19 million.
"They also understand the challenge now is to drive the software sales and revenue much faster in 2026."
What happens if one unseen pressure on that software heavy model shifts margins just as AI demand accelerates?
That margin squeeze risk is exactly what sits at the heart of the full narrative for ImExHS , which maps how ImExHS could accelerate or stall from here.
Singular Health Group (ASX:SHG)
Singular Health Group builds 3DICOM, a medical imaging platform that turns CT, MRI, and PET scans into 3D models and increasingly runs AI in the Cloud to sharpen visualisation. This underpins its A$1.9 million in software revenue and A$58.7 million market cap.
Singular Health Group aims to plug AI directly into the imaging pipes of healthcare, turning raw scan data into richer, cloud-based views that can speak to both clinicians and payers.
"The Florida Medicaid Imaging Repository, backed by US$3m in state funding with about US$2.5m expected to relate to Singular Health technical delivery once definitive agreements are completed, introduces a new infrastructure revenue stream that could support both top line growth and a higher contribution margin as the platform is reused across programs."
The real swing factor now is whether those early networks prove enough savings to support pricing power and more resilient margins.
If those savings really start to show up, full narrative for Singular Health Group explains how Singular Health Group could convert early infrastructure wins into faster-growing software economics and why some risks may be masking upside.
Artrya (ASX:AYA)
Artrya develops Salix, a cloud based AI platform that scans coronary CT angiography images to flag coronary artery disease, and currently records A$0.03 million from its AI driven CCTA analysis technology in Australia, backed by a market cap of about A$451.4 million.
Where ImExHS and Singular Health tackle imaging from radiology and 3D visualisation angles, Artrya goes straight at cardiology risk, using AI on coronary CT scans to help clinicians spot dangerous plaque and blood flow issues before a heart attack.
"Growing adoption of CCTA as a front-line tool for chest pain assessment, together with up to 400,000 scans a year across SAPPHIRE partners at a blended rate of about US$850 per scan across three modules, gives Artrya a clear volume pathway that directly targets future subscription and fee per scan revenue."
What really moves the needle from here is how one assumption about future scan mix plays out against the current cost base and pricing power.
Those scan mix assumptions are exactly what the full narrative for Artrya unpacks, showing how Artrya's model could accelerate or stall as CCTA volumes and pricing power shift.
Seeking Alternatives Before The Crowd?
Some themes move from quiet to crowded fast. Fresh ideas can build momentum while screens still flag them as under the radar for now. Scan the next breakout group and consider your options early.
-
Spot cash generative opportunities early and review the 1 high quality undervalued stocks before attention increases and pricing power shifts away from patient investors.
-
Assess structural demand linked to electrification and review the 16 top copper producer stocks while producers are still priced as if growth has barely started.
-
Target income that aims to hold up when rates change and filter for the 4 dividend fortresses before yields adjust and entry yields compress.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
